FY26 Organic Revenue Outlook Adjusted to -1% to 2%

Sees FY26 total organic revenue, which excludes the impact of foreign exchange and the contribution from the acquisition of UK Biocentre Limited, is now expected to range between (2%)-1% relative to FY25, compared to prior guidance of 3%-5% growth. Organic revenue for Sample Management Solutions is now expected to grow approximately low-single-digits, versus prior expectations of mid-single-digit growth. Organic revenue for Multiomics is now expected to decline approximately mid-single-digits, versus prior expectations of low-single-digit growth. Adjusted EBITDA margin is now expected to decline in a range of approximately 125 basis points to flat relative to FY25, compared to prior expectations of approximately 300 basis points expansion. This outlook excludes an expected dilution of approximately 35 basis points from the UK Biocentre acquisition. Free Cash flow is now expected to improve approximately 10%-15% year-over-year, compared to prior expectations of approximately 30% improvement.